Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer by Tomasz Byrski et al.
RESEARCH ARTICLE Open Access
Results of a phase II open-label, non-randomized
trial of cisplatin chemotherapy in patients with
BRCA1-positive metastatic breast cancer
Tomasz Byrski1, Rebecca Dent2, Pawel Blecharz3, Malgorzata Foszczynska-Kloda4, Jacek Gronwald5,
Tomasz Huzarski5, Cezary Cybulski5, Elzbieta Marczyk3, Robert Chrzan6, Andrea Eisen2, Jan Lubinski5 and
Steven A Narod7*
Abstract
Introduction: The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1
mutation carriers with metastatic breast cancer.
Methods: In a phase II, open-label study, 20 patients with metastatic breast cancer who carried a mutation in
BRCA1 were treated with cisplatin 75 mg/m2 intravenously every 3 weeks as part of a 21-day cycle for 6 cycles.
Restaging studies to assess response were performed after cycles 2 and 6, and every three months thereafter.
Results: Between July 2007 and January 2009, 20 patients were enrolled. Baseline characteristics were as follows:
65% had prior adjuvant chemotherapy, 55% had prior chemotherapy for metastatic breast cancer; mean age was
48 years (ranges 32 to 70); 30% estrogen receptor (ER) or progesterone receptor (PR)+, 70% ER/PR/Human
Epidermal Growth Factor Receptor 2 (HER2)- and 0% HER2+. Overall response rate was 80%; nine patients
experienced a complete clinical response (45%) and seven experienced a partial response (35%). Overall survival
was 80% at one year, 60% at two years and 25% at three years. Four of the 20 patients are alive four years after
initiating treatment. The median time to progression was 12 months. The median survival from the start of
cisplatinum treatment was 30 months. Cisplatin-related adverse events, including nausea (50%), anemia (5%) and
neutropenia (35%) were mostly mild to moderate in severity.
Conclusions: This phase II study demonstrates that cisplatin chemotherapy has high activity in women with a
BRCA1 mutation and metastatic breast cancer and is generally well tolerated.
Trial registration: This trial is registered retrospectively on the clinical trials website ClinicalTrials.gov. The identifier
is NCT01611727.
Introduction
Among women with a BRCA1 mutation and breast cancer,
choice of chemotherapy is a critical issue. There are emer-
ging data which suggest that mutation carriers may
respond differently than non-carriers to particular agents
[1-3]. BRCA1-associated cancers differ from non-hereditary
cancers for a range of pathologic and molecular factors,
including tumor grade and histologic appearance [4-7].
Several studies have shown that the response to treatment
for women with a BRCA1-associated breast cancer reflects
the underlying tumor biology, in particular, the impairment
of the DNA damage response and repair pathways, and
that it is possible to exploit the sensitivity of BRCA1-
associated cancers to DNA damage [8,9].
This study was performed as a component of a large,
multi-center research program conducted in Poland at
the Pomeranian Medical University, which is designed to
characterize the hereditary burden of breast cancer in the
country and to identify and evaluate means of prevention,
screening and treatment for women with BRCA1 muta-
tions. There are three BRCA1 founder mutations in
Poland (5382insC, C61G and 4153delA), which account
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for the great majority of all BRCA1 mutations in Polish
families [10-12].
We have previously reported, in a small study of
BRCA1-positive women with early breast cancer, that a
high rate of complete pathologic response was achieved
using cisplatin chemotherapy as a single agent in the neo-
adjuvant setting [13]. It is equally important that we evalu-
ate the benefit of cisplatin in women with disseminated
breast cancer, including those who have previously been
treated with one or more chemotherapy regimens. This
study was undertaken to evaluate the efficacy of cisplatin
chemotherapy in BRCA1 carriers with metastatic breast
cancer. The primary objective was to determine the objec-
tive response rate of cisplatin in BRCA1 carriers with
metastatic breast cancer. The secondary objectives were to
determine three-year survival and to evaluate the toxicities




Female patients age ≥18 years, with measurable (defined
by Response Evaluation Criteria in Solid Tumors
(RECIST) criteria [14]) metastatic (stage IV) breast cancer,
and who were known to carry a BRCA1 mutation, were
eligible. In addition, the following were required: adequate
hematologic, renal and hepatic function; adequate recov-
ery from recent surgery and/or radiation therapy; recovery
from all prior treatment-related toxicities (to grade <2
according to National Cancer Institute Common Toxicity
Criteria, Version 3.0, except alopecia); life expectancy of at
least 12 weeks; and an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1. Patients
could have received up to four prior chemotherapies for
metastatic disease. Patients with known brain metastases
were not eligible. Patients previously treated with a plati-
num-based chemotherapy were not eligible.
The protocol was approved by the Ethics Committee of
the Pomeranian Medical University with jurisdiction over
the specific sites that registered patients on the study. The
study was approved by Ethics Committee of the Pomera-
nian Medical University BN-001/83/07
Patients were recruited from three academic hospitals in
Poland. All patients provided written informed consent
before enrollment.
Study design and treatment
This was a Phase II, open-label, non-randomized, multi-
center study. Cisplatin (Ebewe, Austria) chemotherapy was
administered as a 75 mg/m2 intravenous (IV) infusion
every three weeks, for six cycles. Dexamethasone (8 mg)
(PABI-Dexamethason, Polfa, Pabianice, Poland) was admi-
nistered once daily for three days after chemotherapy.
Ondansetron (Zofran™) (Zofran, GlaxoSmithKline, Great
Britain was used for anti-nausea prophylaxis.
A total of 18 of the 20 patients received additional lines
of chemotherapy subsequent to platinum therapy at the
time of progression. These included AT (Doxorubicin,
Ebewe, Austria and Docetaxel, Sanofi-Aventis, Poland)
(eight patients) ACT (Doxorubicin, Ebewe, Austria and
Cyclophosphamide, Baxter, Poland and Docetaxel, Sanofi-
Aventis, Poland) (two patients), FAC (5-Fluorouracil,
Ebewe, Austria and Doxorubicin, Ebewe, Austria and
Cyclophosphamide, Baxter, Poland) (two patients) and AC
(Doxorubicin, Ebewe, Austria and Cyclophosphamide,
Baxter, Poland) (one patient. Four patients received an
aromatase inhibitor after platinum therapy.
Assessments
Baseline assessments included the following: medical his-
tory, complete physical examination, assessment of perfor-
mance status on the ECOG scale, physical and radiological
examination of the tumor, and complete blood count
(CBC) and complete metabolic profile. Hormone (estrogen
receptor (ER)/progesterone receptor (PR)) and Human
Epidermal Growth Factor Receptor 2 (HER2) receptor sta-
tus were performed locally. During treatment, these
assessments were performed in the same manner at the
start (Day 1) of each cycle, except radiological examination
of the tumor which was performed after Cycle 2 and Cycle
6, and every three months thereafter.
Response criteria and toxicity
Objective tumor response rate, defined as the percentage
of patients who achieved a complete response or partial
response by RECIST criteria [14], was the primary efficacy
end-point. Radiological assessments were carried out via
computerized tomography at baseline, after two cycles
(6 weeks), after six cycles (18 weeks) and every 3 months
thereafter. Secondary end points included one-year survi-
val and toxicity. Safety assessments included adverse
events, clinical laboratory tests, ECOG patient safety and
physical examinations and vital signs. Adverse events were
graded according to the National Cancer Institute Com-
mon Toxicity Criteria (CTC), version 2.0. After comple-
tion of six cycles of cisplatin, the patient was seen in the
clinic every two weeks for eight weeks and every four
weeks thereafter. A repeat CT scan was done at three-
monthly intervals to evaluate progressive disease.
Statistical analysis
The primary objective of this study was to determine the
overall response rate of cisplatin in metastatic breast can-
cer patients with a known BRCA1 mutation (complete or
partial response). Secondary objectives for this study
included estimating the one-, two- and three-year rates
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of overall survival and the evaluation of toxicity. The
intent-to-treat (ITT) population was defined as all eligi-
ble patients enrolled in the study that had no major viola-
tions of protocol inclusion and/or exclusion criteria.
The response rate was calculated as the number of
responders (best study response recorded as complete
response or partial response) divided by the number of
patients enrolled. Survival was calculated using the
Kaplan-Meier methods. Patients were followed from the
date of first receiving cis-platinum until the date of first




Between July 2007 and January 2009, 20 women were
enrolled in the study. No prospective patient was found
to be ineligible or declined to participate. All study
patients had been tested previously for the presence of
three BRCA1 founder mutations and had been found to
be positive. Eighteen patients were treated in Szczecin
and two were treated in Krakow.
Patient characteristics are summarized in Table 1.
This patient population was notable for its young age
(median age 48 years), predominance of 5382insC
BRCA1 mutations, and predominance of triple-negative
cancers (70%). More than one-half of the patients had
been treated previously with chemotherapy for meta-
static disease. The median disease-free interval from the
first diagnosis of breast cancer until the time of meta-
static disease was 2.2 years. No woman had a prior his-
tory of ovarian cancer or of another form of cancer.
Of the 20 patients enrolled in the study, 17 completed
six cycles of cisplatin chemotherapy. Two patients did not
complete treatment due to disease progression. One
patient discontinued therapy after four cycles due to grade
4 neutropenia. Five patients delayed treatment due to neu-
tropenia or anemia. One patient required blood transfu-
sion. One patient continued to exhibit tumor shrinkage
after six cycles and thus, at the treating physician’s discre-
tion, received nine cycles of chemotherapy.
Treatment outcomes
Responses of the patients are summarized in Table 2. The
overall response rate was 80% (complete response 45%;
partial response 35%). Those patients who responded
included 8 of 9 women for whom cisplatin was their first-
line treatment for metastatic disease (89%) and 8 of 11
women (73%) who had previously been treated for meta-
static disease. A partial or complete response was achieved
in 11 of 12 patients with disease at one site (92%), and in 5
of 8 patients with disease at multiple sites (63%). A partial
or complete response was achieved in 12 of 15 ER-nega-
tive patients (80%), and in 4 of 5 ER-positive patients
(80%). A complete response was achieved in 8 of 15 ER-
negative patients (53%), compared to only 1 of 5 ER-posi-
tive patients (20%). A complete response was achieved in
7 of 14 triple-negative breast cancer patients (50%). A
complete response was observed in 5 of 12 patients with a
5382insC mutation and in 4 of 7 patients with a C61G
Table 1 Characteristics of patients in the study
Age, years
Mean (range) 48.0 (32 to 70)




Year of initial treatment
2000 to 2003 2
2004 to 2006 7




























Prior chemotherapy for metastatic disease
Yes 11
No 9
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mutation (OR = 0.54; P = 0.6; Fishers exact test). Of the
nine women who had a complete response, all were deter-
mined on the basis of the scan four months after stopping
treatment. An example of CT scans, pre- and post-treat-
ment for a woman who experienced a complete response
is shown in Figure 1.
Progression-free survival
All 20 patients have now experienced progression. The
median time to progression was 12 months (range 1 to
36 months). The proportion of patients experiencing
progression was 55% at one year, 80% at two years and
95% at three years (Figure 2a). Among the nine patients
who experienced a complete response, the median time
to progression was 17 months.
Overall survival
The actuarial survival rate for the cohort was 80% at
one year, 60% at two years and 25% at three years
(Figure 2b). The median survival was 30 months. Four
of the 20 patients are currently alive (20%). Each of
these four patients has survived four years or more from
the initiation of cisplatinum treatment. Of these, three
experienced a complete response and one a partial
Table 2 Distribution of response types among patients treated with cis-platinum
Response Number Evidence of progression Time to progression Median (months) Number deceased
Complete 9 9 17 6
Partial 7 7 8 6
Stable 3 3 3 3
Progressive 1 1 1 1
    
 
Figure 1 CT images of pre- and post-treatment for patient experiencing a complete response. Upper left: pre-treatment axial-mediastinal
window. Upper right: post-treatment axial mediastinal window. Lower left: pre-treatment sagittal-mediastinal window. Lower right: post-
treatment sagittal-mediastinal window.
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response. The times elapsed from initiation of treatment
for each of the four living patients was 50, 50, 54 and
62 months. Four patients had a time to progression of
two years or longer. They are described in Table 3.
Toxicity
Treatment-related toxicities are summarized in Table 4.
Cisplatin was generally well tolerated. Consistent with
previous cisplatin studies, the most common adverse
a) 
b) 
Figure 2 Progression after initiation of cisplatin treatment. b) Survival after initiation of cisplatin treatment.
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events were nausea (50%), anemia (5%) and neutropenia
(35%). A grade 3/4 adverse event occurred in two
patients; for both of these, cisplatin was the third-line
treatment. A total of 20% of the patients required dose
adjustment and/or treatment interruption because of
anemia or neutropenia. One patient discontinued cispla-
tin due to neutropenia.
Discussion
There has been a recent resurgence in interest in evalu-
ating platinum-based chemotherapies in patients who
are known to have an inherited deficiency in DNA
repair [15]. An early study evaluating the role of
cisplatin in the first-line therapy of metastatic breast
cancer showed an overall response rate of 47% [16]. In
our study, a partial or complete clinical response was
achieved in 16 of 20 (80%) patients with a BRCA1 muta-
tion and metastatic breast cancer who received cis-plati-
num chemotherapy as a single agent. The median
survival time from the start of cisplatinum treatment
was 30 months.
There are few studies which report on the survival
experiences of cohorts of BRCA1 patients. In a recent
study from the Netherlands, Kriege et al. reported on 93
women with a BRCA1 mutation and metastatic breast
cancer who were treated with conventional chemother-
apy (CMF (Cyclophosphamide, methotrexate, 5-Fluor-
ouracil, or anthracycline-based) [17]. The objective
response rate was 66% and the median progression-free
survival was 7.6 months. In our study, the median time
to progression was 12 months. The median overall sur-
vival in the Kriege study was 15 months, versus 30
months in our study. In an early report of metastatic
breast cancer patients treated with the PARP inhibitor
olaparib, 33 BRCA1 carriers were included [18]. The
median time to progression was approximately four
months for those treated with 100 mg of olaparib twice
a day and was seven months for those treated with 400
mg twice a day (specific figures for the BRCA1-positive
subgroup are not given). Thus, the patients in the cur-
rent study who have been treated with cisplatin appear
to have superior outcomes to these historical controls.
However, it is difficult to compare the survival experi-
ence of different patient cohorts who may have different
disease patterns and different baseline characteristics.
The numbers of BRCA1 carriers in these studies are not
large and some of the variation may be due to random
fluctuation.
It is of interest to try to identify predictors of response
in these patients to determine which women are more
likely to benefit from cisplatin chemotherapy. Our study
Table 3 Characteristics for four study subjects that had a time to progression of two years or longer
Case number
1 13 6 2
BRCA1 mutation C61G C61G 5382insC 5382insC
Age at treatment 56 34 48 66
Estrogen receptor Negative Negative Positive Negative
Progesterone receptor Positive Negative Positive Negative
HER2 status Negative Negative Negative Negative
Site of metastases Lung Lung, liver Liver Liver
Number of sites of metastases 1 2 1 1
Prior adjuvant chemotherapy Yes Yes Yes Yes
Line of therapy of metastatic disease 1 3 1 2
Response Complete Complete Partial Partial
Time from treatment to progression (months) 36 27 27 28























Byrski et al. Breast Cancer Research 2012, 14:R110
http://breast-cancer-research.com/content/14/4/R110
Page 6 of 8
was too small to be definitive in this regard, but it is of
interest that the past use of chemotherapy for metas-
tases was associated with a lower response rate, as was
the presence of disease at multiple sites. Also, only 1 of
5 patients with ER-positive breast cancer had a complete
response, compared to 8 of 15 ER-negative breast can-
cers. However, the numbers of patients in these sub-
groups were small and it is too early to make definite
conclusions in this regard.
The results of this study are consistent with our ear-
lier results of the use of cisplatin as a neo-adjuvant
treatment of breast cancer. In a study of 102 BRCA1
carriers who received neo-adjuvant chemotherapy, 10 of
12 women with a BRCA1 mutation who were given cis-
platin experienced a complete pathologic response
(83%), compared to 14 of 90 patients (16%) treated with
other regimens (P < 0.001; exact test) [19]. To date, we
do not have experience in the use of cisplatin for
patients with metastatic breast cancer who had earlier
received cisplatin in the adjuvant or neo-adjuvant set-
ting. Studies of ovarian cancer patients might be more
informative in this regard. Tan et al. found that patients
with ovarian cancer and a BRCA1 mutation often
responded to cisplatin on multiple occasions during the
course of their treatment [20]. This is in keeping with
an earlier study by Cass et al., who reported that
women with ovarian cancer and a BRCA1 mutation
were more likely than non-carriers to respond well to
cisplatin [21]. Swisher at al. documented revertant
mutations in four of the six recurrent platinum-resistant
ovarian cancers [22]. These secondary mutations
restored the reading frame of the BRCA1 protein. We
do not have data on the mechanisms of eventual resis-
tance to cis-platinum and it will be of interest to estab-
lish whether revertant mutations are also a source of
platinum resistance in breast cancer.
In a mouse model which expressed BRCA1 mutations
in mammary tissue, Drost et al. found that tumors asso-
ciated with the C61G mutation had, on average, a
poorer response to platinum-based drugs than did mice
with tumors that were homozygous null for BRCA1
[23]. There is no evidence in our clinical study that
patients with the C61G mutation were less responsive to
platinum than were patients with the more common
5382insC mutation.
There are several limitations to this study. This is a
relatively small sample of patients (n = 20) and they ori-
ginate from three institutions. Nevertheless, this is
among the largest series of BRCA1 carriers with meta-
static breast cancer to be studied to date, and the under-
lying Polish population is relatively homogeneous. We
conducted computed tomography (CT) scans after two
and six cycles due to the constraints of the institutions
and, therefore, it is challenging to accurately assess
stable disease, duration of response and time to progres-
sion. Ideally, we would have had more frequent scans
and we would have assessed disease at 16 weeks as well.
However, the data regarding overall survival are perhaps
the most striking and this endpoint is straightforward to
evaluate. A total of 18 of the 20 patients were treated
with subsequent lines of chemotherapy after platinum
therapy and, therefore, it is not possible to dissociate
the effect of the cis-platinum therapy from that of other
drugs.
Conclusions
In conclusion, our data suggest that chemotherapy regi-
mens with cisplatin may benefit patients with metastatic
breast cancer and a BRCA1 mutation. These early
results are encouraging, but they should be confirmed in
a larger randomized controlled trial.
Future studies should evaluate the potential of using
this therapy for the treatment of hereditary breast can-
cer due to other genes, including BRCA2. Given that
there do not appear to be founder mutations in BRCA2
in Poland, it will be necessary that these studies be con-
ducted in other countries (or provinces) where BRCA2
founder mutations are prevalent (for example, Quebec)
[24]. Other agents that target DNA repair deficiency
may also prove to be beneficial in this subgroup of
patients.
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